Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance

다국어 초록 (Multilingual Abstract)

Purpose: To investigate germline and somatic mutation profiles in Korean patients with prostate cancer using liquid biopsy and solid tissue testing and to evaluate the prognostic value of circulating tumor DNA (ctDNA) in predicting castration resistance in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Materials and Methods: Plasma samples from 56 prostate cancer patients were subjected to next-generation sequencing (NGS) to identify germline mutations and ctDNA analysis using liquid biopsy to detect somatic mutations. Additionally, paired solid cancer tissues from 18 patients were subject to NGS to detect somatic mutations. The clinical parameters and ctDNA profiles of patients with mHSPC were analyzed to evaluate the prognostic value of ctDNA mutations with respect to predicting castration resistance using Cox proportional hazards regression analysis.
Results: Germline mutations occurred in 3.6% of the patients in this cohort, with mutations identified in RAD50 (1.8%) and BRCA1 (1.8%). Somatic mutations detected by liquid biopsy and solid tissue testing were common in TP53 (12.5%), PIK3CA (3.6%), and TMPRSS2-ERG (3.6%). Of the 18 patients with paired tissue testing, two patients had at least one identical somatic mutation in both the liquid biopsy and solid tissue testing. In patients with mHSPC, the presence of ctDNA mutations could independently predict the castration resistance development (hazard ratio, 13.048; 95% confidential interval, 1.109–153.505; p=0.041).
Conclusions: Korean patients with prostate cancer showed a relatively low germline mutation rate compared to other ethnicities. The ctDNA mutations detected by liquid biopsy can predict the development of castration resistance in patients with mHSPC.

참고문헌 (Reference)

1 Cancer Genome Atlas Research Network, "The molecular taxonomy of primary prostate cancer" 163 : 1011-1025, 2015

2 Nicolosi P, "Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines" 5 : 523-528, 2019

3 Liu Z, "Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC" 8 : 1045-1050, 2019

4 Benafif S, "PRACTICAL Consortium. A review of prostate cancer genome-wide association studies (GWAS)" 27 : 845-857, 2018

5 Todd M. Morgan, "Liquid biopsy: Where did it come from, what is it, and where is it going?" 대한비뇨의학회 60 (60): 139-141, 2019

6 Pritchard CC, "Inherited DNA-repair gene mutations in men with metastatic prostate cancer" 375 : 443-453, 2016

7 강민용, "Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing" 대한비뇨의학회 60 (60): 227-234, 2019

8 Lambert AW, "Emerging biological principles of metastasis" 168 : 670-691, 2017

9 Klein EA, "Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: the Circulating Cell-free Genome Atlas (CCGA) study" 36 (36): 12021-, 2018

10 Scher HI, "Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone : recommendations of the Prostate Cancer Clinical Trials Working Group" 26 : 1148-1159, 2008

11 Wyatt AW, "Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer" 109 : djx118-, 2017

12 Lorente D, "Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts" 29 : 1554-1560, 2018

13 de Bono JS, "Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer" 14 : 6302-6309, 2008

14 Goldkorn A, "Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421 : a phase III metastatic castration resistant prostate cancer trial" 136 : 1856-1862, 2015

15 Heller G, "Circulating tumor cell number as a response measure of prolonged survival for metastatic castrationresistant prostate cancer : a comparison with prostate-specific antigen across five randomized phase III clinical trials" 36 : 572-580, 2018

16 Annala M, "Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer" 8 : 444-457, 2018

17 Sweeney CJ, "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer" 373 : 737-746, 2015

18 Schumacher FR, "Association analyses of more than 140, 000 men identify 63 new prostate cancer susceptibility loci" 50 : 928-936, 2018

19 AACR Project GENIE Consortium, "AACR Project GENIE : powering precision medicine through an international consortium" 7 : 818-831, 2017